The loan will support general business operations for Cerapedics, including the advancement of the company’s United States regulatory process. Cerapedics also recently announced the preliminary outcomes data from the FDA investigational device exemption clinical trial for i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion procedures.
The preliminary results indicted the i-FACTOR bone graft met pre-specified primary end points.
More Articles on Orthopedic Devices:
ConforMIS iTotal Knee Shows Promising Clinical Study Results
Ortho Development Gets FDA Clearance for Ovation Tribute Hip Stem
DePuy Synthes Power Tools Launches Anspach EG1 High Speed Electric System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
